Drug intelligence / Profile preview

90Y-ZCE025

Development stage: Preclinical
Modality: Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intraperitoneal Injection

Overview

90Y-ZCE025 is a radiopharmaceutical agent designed for radioimmunotherapy. It consists of a monoclonal antibody labeled with the radioisotope Yttrium-90 (90Y). The monoclonal antibody specifically targets carcinoembryonic antigen (CEA), a protein often expressed on cancer cells. This targeted delivery allows the radioisotope to deliver localized radiation to CEA-expressing tumors, as demonstrated in preclinical models of human colon cancer.

Other names: 90Y-labeled anticarcinoembryonic antigen monoclonal antibodyanti-CEA MAB

Beyond the preview

Go deeper on 90Y-ZCE025.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on 90Y-ZCE025.

Explore the full profile